Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy in Patients with cN0, T1 or T2 Invasive Breast Cancer By Ogkologos - January 14, 2025 690 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the INSEMA study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Ripretinib for the Treatment... October 5, 2021 Can Chemotherapy Drugs Be Designed to Avoid Side Effects? December 16, 2022 Combining Radiotherapy with SOC Plus Abiraterone Improves rPFS in Patients with... December 5, 2024 Trastuzumab Deruxtecan Demonstrates Efficacy in HER2-positive and HER2-low Advanced Gastric Cancer July 6, 2021 Load more HOT NEWS From smouldering ash to a gleaming temple for cancer research: The... Staging at Presentation for Patients with Localised Pancreatic Ductal Adenocarcinoma Should... Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane... News digest – light-activated nanoparticles, Government’s obesity plans, tumour ‘glue’ and...
